{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+2+Maximum+Tolerated+Dose+determined+in+Phase+1&page=18",
    "query": {
      "intervention": "Phase 2 Maximum Tolerated Dose determined in Phase 1",
      "page": 18
    },
    "page_size": 10
  },
  "pagination": {
    "page": 18,
    "page_size": 10,
    "total_count": 507,
    "total_pages": 51,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+2+Maximum+Tolerated+Dose+determined+in+Phase+1&page=19&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+2+Maximum+Tolerated+Dose+determined+in+Phase+1&page=17&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T04:23:25.552Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03013998",
      "title": "Study of Biomarker-Based Treatment of Acute Myeloid Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Previously Untreated Relapsed Refractory Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Samalizumab (BAML-16-001-S1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BI 836858 (BAML-16-001-S2)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Daunorubicin (BAML-16-001-S1)",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine (BAML-16-001-S1)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S2)",
          "type": "DRUG"
        },
        {
          "name": "AG-221 (BAML-16-001-S3)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S3)",
          "type": "DRUG"
        },
        {
          "name": "Entospletinib (BAML-16-001-S4)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S4)",
          "type": "DRUG"
        },
        {
          "name": "Entospletinib (BAML-16-001-S5)",
          "type": "DRUG"
        },
        {
          "name": "Decitabine (BAML-16-001-S5)",
          "type": "DRUG"
        },
        {
          "name": "Entospletinib (BAML-16-001-S6)",
          "type": "DRUG"
        },
        {
          "name": "Daunorubicin (BAML-16-001-S6)",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine (BAML-16-001-S6)",
          "type": "DRUG"
        },
        {
          "name": "Pevonedistat (BAML-16-001-S9)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S9)",
          "type": "DRUG"
        },
        {
          "name": "AG-120 (BAML-16-001-S16)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S16)",
          "type": "DRUG"
        },
        {
          "name": "Gilteritinib (BAML-16-001-S8 Group 1)",
          "type": "DRUG"
        },
        {
          "name": "Decitabine (BAML-16-001-S8 Group 1)",
          "type": "DRUG"
        },
        {
          "name": "AZD5153 (BAML-16-001-S10)",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax (BAML-16-001-S10)",
          "type": "DRUG"
        },
        {
          "name": "TP-0903 (BAML-16-001-S14)",
          "type": "DRUG"
        },
        {
          "name": "Decitabine (BAML-16-001-S14)",
          "type": "DRUG"
        },
        {
          "name": "Decitabine (BAML-16-001-S8 Group 2)",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax (BAML-16-001-S8 Group 2)",
          "type": "DRUG"
        },
        {
          "name": "AZD5991 (BAML-16-001-S18)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S18)",
          "type": "DRUG"
        },
        {
          "name": "SNDX-5613 (BAML-16-001-S17)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S17)",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax (BAML-16-001-S17)",
          "type": "DRUG"
        },
        {
          "name": "Gilteritinib (BAML-16-001-S8 Group 2)",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax (BAML-16-001-S12 Arm A)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S12 Arm A)",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax (BAML-16-001-S12 Arm B)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S12 Arm B)",
          "type": "DRUG"
        },
        {
          "name": "ZE46-0134 (BAML-16-001-S21 Group 1)",
          "type": "DRUG"
        },
        {
          "name": "ficlatuzumab (BAML-16-001-S24)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S24)",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax (BAML-16-001-S24)",
          "type": "DRUG"
        },
        {
          "name": "ZE46-0134 (BAML-16-001-S21 Group 2)",
          "type": "DRUG"
        },
        {
          "name": "Bleximenib (BAML-16-001-S25/HO181)",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine (BAML-16-001-S25/HO181)",
          "type": "DRUG"
        },
        {
          "name": "Daunorubicin or Idarubicin (BAML-16-001-S25/HO181)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (BAML-16-001-S25/HO181)",
          "type": "DRUG"
        },
        {
          "name": "Revumenib (BAML-16-001-S26/HO177)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (BAML-16-001-S26/HO177)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Beat AML, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3000,
      "start_date": "2016-11",
      "completion_date": "2032-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-10-15T04:23:25.552Z",
      "location_count": 31,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03013998"
    },
    {
      "nct_id": "NCT00389922",
      "title": "Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "lapatinib ditosylate",
          "type": "DRUG"
        },
        {
          "name": "Vinorelbine ditartrate",
          "type": "DRUG"
        },
        {
          "name": "comparative genomic hybridization",
          "type": "GENETIC"
        },
        {
          "name": "cytogenetic analysis",
          "type": "GENETIC"
        },
        {
          "name": "gene expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "mutation analysis",
          "type": "GENETIC"
        },
        {
          "name": "polymerase chain reaction",
          "type": "GENETIC"
        },
        {
          "name": "polymorphism analysis",
          "type": "GENETIC"
        },
        {
          "name": "proteomic profiling",
          "type": "GENETIC"
        },
        {
          "name": "reverse transcriptase-polymerase chain reaction",
          "type": "GENETIC"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2005-12",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2012-04-19",
      "last_synced_at": "2026-10-15T04:23:25.552Z",
      "location_count": 4,
      "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 1 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00389922"
    },
    {
      "nct_id": "NCT00004862",
      "title": "Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "oblimersen sodium",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "1999-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-01",
      "last_synced_at": "2026-10-15T04:23:25.552Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004862"
    },
    {
      "nct_id": "NCT02558140",
      "title": "A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "RO6874813",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2015-10-11",
      "completion_date": "2017-11-06",
      "has_results": false,
      "last_update_posted_date": "2018-04-04",
      "last_synced_at": "2026-10-15T04:23:25.552Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02558140"
    },
    {
      "nct_id": "NCT00310024",
      "title": "Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Refractory Multiple Myeloma",
        "Stage I Multiple Myeloma",
        "Stage II Multiple Myeloma",
        "Stage III Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "bortezomib",
          "type": "DRUG"
        },
        {
          "name": "vorinostat",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2005-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-07",
      "last_synced_at": "2026-10-15T04:23:25.552Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00310024"
    },
    {
      "nct_id": "NCT06260774",
      "title": "Study of TTX-MC138 in Subjects With Advanced Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "TTX-MC138",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TransCode Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 16,
      "start_date": "2024-09-05",
      "completion_date": "2027-02-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-02",
      "last_synced_at": "2026-10-15T04:23:25.552Z",
      "location_count": 4,
      "location_summary": "Dallas, Texas • Houston, Texas • West Valley City, Utah + 1 more",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "West Valley City",
          "state": "Utah"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06260774"
    },
    {
      "nct_id": "NCT05840510",
      "title": "Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "NSCLC",
        "Advanced Cancer",
        "Metastatic Cancer",
        "Malignant Neoplastic Disease"
      ],
      "interventions": [
        {
          "name": "Adagrasib",
          "type": "DRUG"
        },
        {
          "name": "nab-Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mirati Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2023-08-07",
      "completion_date": "2024-12-27",
      "has_results": false,
      "last_update_posted_date": "2025-04-25",
      "last_synced_at": "2026-10-15T04:23:25.552Z",
      "location_count": 3,
      "location_summary": "Cleveland, Ohio • Nashville, Tennessee • Houston, Texas",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05840510"
    },
    {
      "nct_id": "NCT05270057",
      "title": "Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B-cell Lymphoma",
        "Burkitt Lymphoma"
      ],
      "interventions": [
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Loncastuximab Tesirine 0.075 mg/kg by IV",
          "type": "DRUG"
        },
        {
          "name": "Loncastuximab tesirine 0.12 mg/kg by IV",
          "type": "DRUG"
        },
        {
          "name": "Loncastuximab tesirine 0.15 mg/kg by IV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2023-01-26",
      "completion_date": "2027-10-11",
      "has_results": false,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-10-15T04:23:25.552Z",
      "location_count": 3,
      "location_summary": "Dallas, Texas • Madison, Wisconsin • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05270057"
    },
    {
      "nct_id": "NCT06562907",
      "title": "Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Weight Management"
      ],
      "interventions": [
        {
          "name": "GS-4571",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 134,
      "start_date": "2024-08-28",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-15T04:23:25.552Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • San Antonio, Texas • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06562907"
    },
    {
      "nct_id": "NCT01170286",
      "title": "Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Peanut Allergy"
      ],
      "interventions": [
        {
          "name": "Whole peanut extract",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo formulation",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "DBV Technologies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "6 Years to 50 Years"
      },
      "enrollment_count": 100,
      "start_date": "2010-07",
      "completion_date": "2012-02",
      "has_results": false,
      "last_update_posted_date": "2012-03-23",
      "last_synced_at": "2026-10-15T04:23:25.552Z",
      "location_count": 5,
      "location_summary": "Little Rock, Arkansas • Denver, Colorado • Willingboro, New Jersey + 2 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Willingboro",
          "state": "New Jersey"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Orem",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01170286"
    }
  ]
}